Sowing seeds to embrace science & spirit

Cubed Biotech's groundbreaking R&D program is committed to pushing the boundaries of natural entheogen psychedelic biotechnology.
Our program encompasses an array of initiatives, starting with the cultivation of psilocybe mushrooms—the mystical fungi that have captured the imaginations of humans for centuries. Through meticulous research and cutting-edge techniques, we nurture these sacred mushrooms to harness their full potential...Nature's Gateway.
But that's just the beginning! Our dedicated team of experts then skillfully extract the potent compounds of psilocybin, mescaline, and DMT — nature's mystical trio. We ensure the purity and integrity of these entheogenic substances, maintaining their powerful properties while adhering to strict ethical and safety standards.

Research Sponsorships

We also take great pride in our collaboration with esteemed institutions, where we proudly sponsor research under the guidance of cutting-edge principal investigators. Together, we delve deeper into the realm of entheogens, exploring their therapeutic applications, expanding our knowledge, and pushing the boundaries of scientific understanding.
Join us on this exhilarating journey as we unravel the secrets of nature's psychedelic wonders.


"Reward Pathways in the Brain"

Cubed & McGill received a $575,000 Grant from the Biopharmaceutical Consortium of Quebec (CQDM)
Funding for this project was made possible by a grant from the Ministère de l’Économie et de l’Innovation du Québec.
Working with a CQDM grant of $575,000, Dr. Rosemary Bagot, the principal investigator at McGill University, made significant advances in neuroscience. Her lab developed a translationally relevant mouse model to probe how stress changes the way the brain processes reward. Research using this model could have significant implications for the treatment of depression, addiction and other psychiatric disorders. We congratulate Dr. Bagot and her team on their work. 
The research project aimed to clarify, at the molecular level, the mechanism of action of psilocybin, an agonist of serotonin receptors, in order to better understand its effects on neuronal circuits and the way in which it could reduce symptoms of depression. 



Our sponsorship of Paul Seli, Ph.D’s study is into the effect of psilocybin on political partisanship has begun at Duke University. Dr. Seli will run those who self-identify as being on the "right" or "left" can express more compassion and understanding to "the other side" after therapeutic sessions of psilocybin.